Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy

Abstract

Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. Background Active systemic lupus erythematosus (SLE) can cause fever. Steroids (glucocorticoids) suppress SLE fever; however, the extent to which steroid therapy affects SLE fever not previously been rigorously studied. Methods Study A is a prospective study of recurrently active SLE patients ( N = 92, 60 renal SLE and 32 nonrenal SLE) who recorded daily oral evening temperatures while participating in a longitudinal study of risk factors for SLE flare. Study B is a retrospective study of consecutive febrile SLE patients ( N = 22) who received steroids initially because SLE was suspected. At final analysis 11 had SLE fever and 11 had infection fever. Results In study A during a mean follow-up of 13.2 ± 8.1 months, 51 of the 92 patients experienced 73 SLE flares. In only one patient was SLE fever associated with SLE flare. In the other 50 patients who flared, there was no significant trend to develop fever prior to or at the onset of SLE flare. Prednisone, median dose 10mg, was being received at 82% of the study visits at which an SLE flare was declared. In study B, prednisone 28mg (range 20 to 40mg) completely suppressed SLE fever, usually within 24 hours. In contrast, infection fever persisted despite prednisone 35 to 300mg/day. Of those with infection fever, three developed fatal sepsis when high-dose steroid therapy was continued. Conclusion In SLE patients receiving prednisone at maintenance doses or greater, SLE fever is rare. When fever does develop, it is usually due to infection. Continuing high steroid dose steroid therapy in those with infection fever may increase the risk of severe sepsis.